Fernando Pacheco

Fernando is a Partner at Endeavour Vision focused on medical technology, digital health and diagnostics investments, with a particular focus on orthopaedics, robotics, dental, ophthalmology, ENT and GI. Since joining the firm, he has undertaken multiple sector reviews, led deal screening efforts and participated in and directed a number of due diligence projects. Fernando represents Endeavour Vision as a board member for Miach Orthopaedics, Virtual Incision Corporation and CeQur. He has previously represented Endeavour Vision as a board observer for SOPHiA GENETICS (NASDAQ:SOPH) prior to the company’s IPO in July 2021. He was on deal teams for investments in Miach Orthopaedics, Virtual Incision Corporation, InBrace, Lumeon, SOPHiA GENETICS and CeQur.

Prior to joining Endeavour Vision Fernando was an Engagement Manager at McKinsey & Company. There, he led numerous business strategy and organisational projects including therapeutic-area strategy, merger management, process optimisation, operating model re-design, corporate due-diligence and market access and launch preparation. Fernando worked across multiple geographies, including Switzerland, France, Germany, Belgium, UK, US and Brazil and sectors such as diabetes, specialty pharmaceuticals, infectious disease, wound care, surgical instruments, orthopedics and dental. Before McKinsey, Fernando led the development of several orthopaedic trauma solutions at Stryker Orthopaedics R&D in Switzerland – focusing on upper trauma and extremities.

Fernando holds an MEng degree in Biomedical and Mechanical Engineering from Imperial College London and the Swiss Federal Institute of Technology (ETH) Zürich. His Masters’ thesis was in cardiovascular fluid mechanics of stented arteries.